Trials that use: Risk difference
New to this method? Read the tutorial →
4,772 results
- A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203): Complete Statistical AnalysisIndependent statistical analysis of A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis: Complete Statistical AnalysisIndependent statistical analysis of A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis: primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations: Complete Statistical AnalysisIndependent statistical analysis of A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations: primary endpoint results, effect estimate with confidence interval,…
- A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors: Complete Statistical AnalysisIndependent statistical analysis of A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01825876).
- A Study of Evacetrapib in Healthy Female Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of Evacetrapib in Healthy Female Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01746732).
- A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis: primary endpoint results, effect estimate with confidence interval,…
- A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158): Complete Statistical AnalysisIndependent statistical analysis of A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Study of FMT in Patients With AML Allo HSCT in Recipients: Complete Statistical AnalysisIndependent statistical analysis of A Study of FMT in Patients With AML Allo HSCT in Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04085289).
- A Study of Galcanezumab in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of Galcanezumab in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02576951).
- A Study of Galunisertib in Participants With Myelodysplastic Syndromes: Complete Statistical AnalysisIndependent statistical analysis of A Study of Galunisertib in Participants With Myelodysplastic Syndromes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02008318).
- A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive…
- A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM): Complete Statistical AnalysisIndependent statistical analysis of A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: primary endpoint results, effect…
- A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.: Complete Statistical AnalysisIndependent statistical analysis of A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.: primary endpoint results, effect…
- A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH: Complete Statistical AnalysisIndependent statistical analysis of A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04764474).
- A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy: Complete Statistical AnalysisIndependent statistical analysis of A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Immunogenicity and Safety of GSK Biologicals’ Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older: Complete Statistical AnalysisIndependent statistical analysis of A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older: primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202): Complete Statistical AnalysisIndependent statistical analysis of A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy: primary endpoint results, effect estimate with confidence…
- A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations: Complete Statistical AnalysisIndependent statistical analysis of A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations: primary endpoint…
- A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion: Complete Statistical AnalysisIndependent statistical analysis of A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2): Complete Statistical AnalysisIndependent statistical analysis of A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01385566).
- A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.: Complete Statistical AnalysisIndependent statistical analysis of A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Intravenous Perampanel in Japanese Participants With Epilepsy: Complete Statistical AnalysisIndependent statistical analysis of A Study of Intravenous Perampanel in Japanese Participants With Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03754582).
- A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn’s Disease: Complete Statistical AnalysisIndependent statistical analysis of A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease: primary endpoint results, effect estimate with confidence…
- A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection: Complete Statistical AnalysisIndependent statistical analysis of A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza: Complete Statistical AnalysisIndependent statistical analysis of A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B): Complete Statistical AnalysisIndependent statistical analysis of A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis: Complete Statistical AnalysisIndependent statistical analysis of A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris: Complete Statistical AnalysisIndependent statistical analysis of A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03073213).
- A Study of Ixekizumab in Participants With Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of A Study of Ixekizumab in Participants With Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02993471).
- A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers: Complete Statistical AnalysisIndependent statistical analysis of A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever: Complete Statistical AnalysisIndependent statistical analysis of A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04906980).
- A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors: Complete Statistical AnalysisIndependent statistical analysis of A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy: Complete Statistical AnalysisIndependent statistical analysis of A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy: primary endpoint results, effect estimate with confidence…
- A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH): Complete Statistical AnalysisIndependent statistical analysis of A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH): primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis: Complete Statistical AnalysisIndependent statistical analysis of A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Lasmiditan in Healthy Chinese Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of Lasmiditan in Healthy Chinese Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04081324).
- A Study of Lasmiditan in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of Lasmiditan in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03182920).
- A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Study of Loco-Regional Liposomal Bupivacaine Injection: Complete Statistical AnalysisIndependent statistical analysis of A Study of Loco-Regional Liposomal Bupivacaine Injection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05992896).
- A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus: Complete Statistical AnalysisIndependent statistical analysis of A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus: primary endpoint results, effect estimate…
- A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study of LY2439821 in Rheumatoid Arthritis: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY2439821 in Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01236118).